Friday, 16 October 2026European Markets

AUGROS COSMETICS Stock Bullish By 15% So Far On Tuesday

Loading stream...

on tuesday, augros cosmetics (augr.pa) saw its stock rise 15.56% to eur7.80 after experiencing five consecutive sessions of losses. meanwhile, the cac 40 index experienced a decrease of 1.35% to eur7,220.92, following two straight sessions of gains. this recent activities has sparked a buzz in the stock market, given the volatility experienced.

company profile

france-based augros cosmetics specializes in customized packaging solutions for perfume, cosmetic and spirit industries. despite the current negative market sentiment, their stock price has seen a marked rebound - showing their resilience when facing downturns in market trends.

the numbers at a glance

the trailing twelve months earnings per share (eps) for this company totaled eur0.43, while their price to earnings ratio (per) currently stands at 18.14. this suggests investors are paying eur18.14 per euro of annual earnings and hints at a relatively high valuation.

stock market indicators

according to the stochastic oscillator, a tool often used in technical analysis to signal overbought and oversold conditions, augros cosmetics' stock is considered overbought. this means its shares are trading above their true value and could potentially see corrective price action.

volatility in the market

recently, augros cosmetics has experienced significant volatility. their last week intraday variation average was negative 4.99%, while over the past month, it has averaged positive 0.02%. these figures indicate the degree of uncertainty or risk associated with large changes to its stock value.

looking ahead

augros cosmetics' ability to rebound indicates strong prospective performance despite market challenges. however, investors should keep an eye on its high valuation and overbought condition. this state may signal a potential market correction down the road.

more news about augros cosmetics (augr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com